Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06648876
PHASE1

PK and PD of YG1699 in CKD Patients With Diabetes

Sponsor: RenJi Hospital

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn PK and PD of YG1699 in patients with diabetes and renal dysfuction. Participants will: Take YG1699 or a placebo every day for 8 days. Visit the clinic 7 times for checkups and tests. Keep a diary of their symptoms. Estimate PK data from a single dose of YG1699. Estimate PD data at baseline and the last day.

Official title: Pharmacokinetic and Pharmacodynamics of YG1699 in Patients With Diabetes and Kidney Dysfunction

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2024-10-31

Completion Date

2025-10-30

Last Updated

2024-10-18

Healthy Volunteers

No

Interventions

DRUG

YG1699

10mg qd for 8 days

DRUG

Placebo

10mg qd for 8 days

Locations (1)

Department of nephrology , Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China